Theres no doubt about MSB posters here. You guys can spot dodgy clinical trial results a mile away.
And its really not that difficult is it.
Every company trying to fool the market does exactly the same first move.
It fails to present the numerical values on the primary outcome. And everything from after that point is just one big fairy story.
In terms CYDY only having 19 employees?
According to the detractors the CYDY CEO is very charismatic, forceful, clever and hugely overpaid. Well that’s not in itself hugely unusual.
But what about if you worked for two CEO’s that were the same but in two different companies; in quick succession; running P3 Covid trials, that failed, but the companies said were great successes and one may have been your fault … but the other wasn’t …
The chances would have to be a million to one surely …
Analysis of the EAP, page-1068
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.15 |
Change
0.045(4.07%) |
Mkt cap ! $1.313B | |||
| Open | High | Low | Value | Volume |
| $1.08 | $1.16 | $1.08 | $4.681M | 4.170M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 99680 | $1.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.16 | 31000 | 2 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |